Zinc Sulfate add-on therapy compared to risperidone alone in schizophrenia: a double-blind, randomized, placebo-controlled clinical trial
Phase 2
- Conditions
- Schizophrenia.Schizophrenia, unspecified
- Registration Number
- IRCT138801241457N3
- Lead Sponsor
- Mazandaran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
DSM-IV-TR criteria for schizophrenia, PANSS score more than 80, no anti psychotic consumption or seven half-life, the drug was wash out
Exclusion criteria: other psychiatric disorders such as substance dependence and physical illnesses, such as liver and renal failure, cardiovascular diseases, allergic and immune system disorders etc.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Severity of symptoms. Timepoint: Baseline and 2nd, 4th, and 6th week. Method of measurement: Positive and Negative Syndrome Scale (PANSS).
- Secondary Outcome Measures
Name Time Method The speed of risperidone antipsychotic effect. Timepoint: Baseline and 2nd, 4th, and 6th week. Method of measurement: Positive and Negative Syndrome Scale (PANSS).